What's Happening?
The World Health Organization (WHO) has recommended two experimental vaccine candidates, ChAdOx1 BDBV from the University of Oxford and mRNA-1469 from Moderna, for inclusion in the ongoing Phase 2/3 Tumaini trial in the Democratic Republic of the Congo
(DRC). This trial aims to assess the effectiveness of these vaccines against the Bundibugyo virus, which is responsible for a significant Ebola outbreak in the DRC. The candidates will join Ervebo, an existing Ebola vaccine whose efficacy against Bundibugyo virus is currently unknown. Both new candidates have demonstrated encouraging results in animal studies and early clinical trials in the UK and Canada, showing their ability to safely stimulate immune responses in humans. The ChAdOx1 BDBV vaccine utilizes a modified chimpanzee adenovirus to deliver genetic instructions for a Bundibugyo virus protein, while mRNA-1469 uses messenger RNA (mRNA) technology. These technologies were previously used in COVID-19 vaccines, providing insights into their safety profiles.
Why It's Important?
The inclusion of these two new vaccine candidates in the Tumaini trial is a critical step towards developing effective countermeasures against the Bundibugyo virus, which has caused the second-largest Ebola outbreak in history. While an effective vaccine exists for the Ebola virus (Zaire ebolavirus), there is currently no licensed vaccine specifically targeting Bundibugyo. The ongoing outbreak in the DRC has resulted in nearly 11,000 cases and over 5,300 deaths, highlighting the urgent need for a dedicated vaccine. The trial's success could lead to a significant reduction in morbidity and mortality associated with Bundibugyo virus disease, strengthening global health security. Furthermore, the use of established vaccine technologies from the COVID-19 pandemic could accelerate the development and deployment process, offering a quicker path to protection for affected communities.
What's Next?
The two vaccine candidates will enter the Tumaini trial following national approvals in the DRC. The trial will employ a ring-guided vaccination strategy, where individuals who have been in contact with confirmed Ebola cases will be vaccinated. Participants will be randomly assigned to receive either an Ebola vaccine or a comparator vaccine and will be monitored for signs of disease. Results from the trial are anticipated in early 2027. If a vaccine proves effective, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) have a joint 'push-pull' financing strategy in place to accelerate vaccine development and manufacturing, ensuring sufficient doses are available. WHO is expected to grant Emergency Use Listing (EUL) and/or Prequalification once sufficient safety and efficacy data are available, facilitating broader deployment.
Beyond the Headlines
The development and testing of these Bundibugyo vaccine candidates underscore the evolving landscape of global health security and the proactive measures being taken to combat emerging infectious diseases. The 'push-pull' financing mechanism by Gavi and CEPI addresses a critical challenge in vaccine development for rare and unpredictable outbreaks: the lack of commercial incentive for manufacturers. This innovative funding model aims to de-risk investment in vaccine production, ensuring that effective vaccines can be rapidly scaled up and deployed during outbreaks. The long-term goal is to establish a global stockpile of Ebola Bundibugyo vaccines, mirroring the existing stockpile for Ebola Zaire vaccines. This strategic preparedness is crucial for protecting communities worldwide from devastating viral threats and highlights the importance of international collaboration in public health.
